MindMed Lists On NEO To Become World’s First Psychedelic Pharmaceutical Company To Go Public

On March 3, 2020, Neo Exchange Inc. (NEO) announced it had granted final approval to Mind Medicine Inc. (MindMed), a neuro-pharmaceutical company for psychedelic-inspired medicines, to make its global public markets debut. MindMed will begin trading on March 3 on the NEO Exchange under the symbol NEO:MMED, and is expected to become the world’s first publicly traded psychedelic pharmaceutical company. The company recently raised $24.2 million USD in a pre-public funding round. Investors can trade shares of NEO:MMED through their usual investment channels, including discount brokerage platforms and full-service dealers.

MindMed develops . . .